%0 Journal Article
%A Fernandez-Martinez, Aranzazu
%A Pascual, Tomás
%A Perrone, Giuseppe
%A Morales, Serafin
%A de la Haba, Juan
%A González-Rivera, Milagros
%A Galván, Patricia
%A Zalfa, Francesca
%A Amato, Michela
%A Gonzalez, Lucia
%A Prats, Miquel
%A Rojo, Federico
%A Manso, Luis
%A Paré, Laia
%A Alonso, Immaculada
%A Albanell, Joan
%A Vivancos, Ana
%A González, Antonio
%A Matito, Judit
%A González, Sonia
%A Fernandez, Pedro
%A Adamo, Barbara
%A Muñoz, Montserrat
%A Viladot, Margarita
%A Font, Carme
%A Aya, Francisco
%A Vidal, Maria
%A Caballero, Rosalía
%A Carrasco, Eva
%A Altomare, Vittorio
%A Tonini, Giuseppe
%A Prat, Aleix
%A Martin, Miguel
%T Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.
%D 2017
%U https://hdl.handle.net/10668/25130
%X PAM50/Prosigna gene expression-based assay identifies three categorical risk of relapse groups (ROR-low, ROR-intermediate and ROR-high) in post-menopausal patients with estrogen receptor estrogen receptor-positive (ER+)/ HER2-negative (HER2-) early breast cancer. Low risk patients might not need adjuvant chemotherapy since their risk of distant relapse at 10-years is below 10% with endocrine therapy only. In this study, 517 consecutive patients with ER+/HER2- and node-negative disease were evaluated for Ki67 and Prosigna. Most of Luminal A tumors (65.6%) and ROR-low tumors (70.9%) had low Ki67 values (0-10%); however, the percentage of patients with ROR-medium or ROR-high disease within the Ki67 0-10% group was 42.7% (with tumor sizes ≤2 cm) and 33.9% (with tumor sizes > 2 cm). Finally, we found that the optimal Ki67 cutoff for identifying Luminal A or ROR-low tumors was 14%. Ki67 as a surrogate biomarker in identifying Prosigna low-risk outcome patients or Luminal A disease in the clinical setting is unreliable. In the absence of a well-validated prognostic gene expression-based assay, the optimal Ki67 cutoff for identifying low-risk outcome patients or Luminal A disease remains at 14%.
%K Ki67
%K PAM50/Prosigna
%K breast cancer
%K estrogen receptor-positive/HER2-negative
%~